Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump
The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump
The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump
Submitted by
admin
on February 15, 2017 - 9:59am
Source:
Endpoints
News Tags:
biotech
biotech executives
Donald Trump
drug pricing
FDA
Headline:
The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump
Do Not Allow Advertisers to Use My Personal information
